Circulating interleukin-10 and interleukin-12 in Parkinson's disease
Department of Neurology, School of Medicine, Athens National University, Athens, Greece. Acta Neurologica Scandinavica
(Impact Factor: 2.4).
10/2008; 119(5):332-7. DOI: 10.1111/j.1600-0404.2008.01103.x
Interleukin (IL)-12 is a heterodimeric cytokine produced by activated blood monocytes, macrophages and glial cells. It enhances differentiation and proliferation of T cells and increases production of proinflammatory cytokines. IL-10 is a pleiotropic cytokine produced by both lymphocytes and mononuclear phagocytes including microglia. Recent studies demonstrated the neuroprotective effect of IL-10. There is little information about the involvement of IL-12 or IL-10 in the pathophysiology of Parkinson's disease (PD).
The objective of our study was to assess the role of IL-12 as a potential marker of immune reactions in patients with PD and to investigate whether IL-10, an immunosuppressive cytokine, may have a neuroprotective effect in the pathogenesis of PD.
We measured using immunoassay serum IL-12 and IL-10 levels in 41 patients with PD in comparison with serum levels in 19 healthy subjects (controls) age and sex matched. IL-12 and IL-10 levels were tested for correlation with sex, age, disease duration, Hoehn and Yahr stage and the UPDRS III score.
The PD group presented with significantly increased IL-10 levels when compared with the control group (P = 0.02). The increase observed was not affected by the treatment status. A strong and significant correlation between IL-10 and IL-12 levels was observed in patients with PD (R(S) = 0.7, P < 0.000001).
Our findings suggest that IL-10 may be involved in the pathogenetic mechanisms of PD. The elevation of IL-10 and the significant correlation between IL-10 and IL-12, a proinflammatory cytokine, may suggest that immunological disturbances and neuroprotective mechanisms are involved in patients with PD.
Available from: Mohadeseh Haji Abdolvahab
- "), while changes in circulating cytokine levels have also been linked to neurodegeneration (Reale and others 2009; Rentzos and others 2009; Scalzo and others 2010). More recently , studies have shown that acute administration of LPS into the substantia nigra of rats leads to elevation of IL-1b, TNF-a, IL-6, and nitric oxide (NO) in this tissue (Herrera and others 2000; Arimoto and others 2007; Hernandez-Romero and others 2008) and increased expression of GDNF immunoreactivity in astrocytes (Iravani and others 2012). "
[Show abstract] [Hide abstract]
ABSTRACT: Aggregation often occurs during manufacturing and storage of protein drugs. Detergents such as sodium dodecyl sulfate are commonly used to prevent aggregation but need to be eliminated before final formulation for safety reasons. We studied the ability of dodecylmaltoside (DDM), a nontoxic alkyl saccharide surfactant, to reduce aggregation and increase the stability of interferon beta-1b (IFN)-β-1b. An increase of 8°C in the Tm of IFN-β-1b was observed when 0.1% of DDM was present in the protein solution. The absorption of DDM on hydrophobic surfaces of IFN-β-1b enables the surface to become hydrophilic and non-ionic, and increases the stability of the protein. 0.1% DDM also results in a 62% increase in helical and a 25% decrease in β-sheet structures. 0.1% DDM not only suppresses aggregate formation but also improves IFN-β-1b solubilization. Furthermore, we have showed the protective effect of DDM on the anti-viral activity of IFN-β-1b in solution.
Available from: Marcel Benadiba
- "Noteworthy, IL-10 is thought to be neuroprotective, while IL-12 is considered a pro-inflammatory cytokine . These results suggest a controlled production of these two molecules in PD pathology, where IL-10 is upregulated when IL-12 levels tends to be increased . Hence, due to the ability of IL-12 in binding in cells that mediate inflammation, Annovazzi and colleagues labelled a food and drug administration (FDA)-approved nonradioactive recombinant human IL-12 (rhIL-12) with 99m Tc ( 99m Tc-IL-12) and evaluated it in a mouse model to detect inflammation . "
[Show abstract] [Hide abstract]
ABSTRACT: The pathophysiology of Parkinson's disease (PD) has not yet been completely elucidated. However, during the past few years, significant progress has been made in understanding the intra- and extracellular mechanisms by which proteins such as alpha-synuclein and neuroinflammatory molecules may display impaired function and/or expression in PD. Recent developments in imaging techniques based on positron emission tomography (PET) and single photon emission computed tomography (SPECT) now allow the non-invasive tracking of such molecular targets of known relevance to PD in vivo. This article summarizes recent PET and SPECT studies of new radiopharmaceuticals and discusses their potential role and perspectives for use in the fields of new drug development and early diagnosis for PD, as well to aid in differential diagnosis and monitoring of the progression of PD.
Available from: Kim Ellefsen
- "IL-10 is a key orchestrator of the immune system with potent anti-inflammatory effects. An increase in IL-10 concentration in the peripheral blood was previously demonstrated in other neurodegenerative disorders, such as PD and HD [26,27]. Although it is less severe, FXTAS shares features with HD including trinucleotide-repeat expansions, the presence of intranuclear inclusions, abnormal movements and cognitive decline. "
[Show abstract] [Hide abstract]
Fragile X-associated tremor/ataxia syndrome (FXTAS) is an inherited late-onset neurodegenerative disorder, characterized both by neurological and cognitive deficits. It is caused by the expansion of CGG repeats (55 to 200 repeats) in the noncoding region of the fragile X mental retardation 1 (FMR1) gene. Abnormal immunological patterns are often associated with neurodegenerative disorders and implicated in their etiology. We therefore investigated the immune status of FXTAS patients, which had not been assessed prior to this study.
Peripheral blood mononuclear cells (PBMCs) were collected from 15 asymptomatic FMR1 premutation carriers and 20 age-matched controls. Concentrations of three cytokines (IL-6, IL-8, IL-10) were measured in PBMC supernatants using ELISA assays.
We found a significant increase in the concentration of the major anti-inflammatory cytokine IL-10 in supernatants of PBMCs derived from premutation carriers, when compared with controls (P = 0.019). This increase correlated significantly with the number of CGG repeats (P = 0.002).
Elevated IL-10 levels were observed in all premutation carriers, before appearance of the classical neurological symptoms; therefore, IL-10 may be one of the early biomarkers of FXTAS.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.